Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lexaria Bioscience Corp.LEXX · Entity 7641 | Chief Financial Officer | October 14, 2022 | October 18, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lexaria Bioscience Corp.
Report date October 14, 2022 · Filed October 18, 2022 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| common sharesSEC Table I · non-derivative | Direct | 1,954 |
Reported balance
After 2022-10-14 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2022-10-14 · Purchase · Acquired 121 · Balance 1,954 F1: This Form 4A is being filed to correct the transaction code for the open market purchase made by Mr. Downey as originally notated as a grant or award in the Form 4 filed on October 18, 2022. |
| common sharesSEC Table I · non-derivative | Direct | 1,833 |
Reported balance
Holding disclosure · report date 2022-10-14 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 1,833 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $5.04 · Expires 2026-04-15 | Direct | 4,000 |
Reported balance
Holding disclosure · report date 2022-10-14 · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · Balance 4,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $5.04 · Expires 2026-04-15 | Direct | 8,000 |
Reported balance
Holding disclosure · report date 2022-10-14 · row 4
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 4 · Balance 8,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $5.04 · Expires 2026-04-15 | Direct | 12,000 |
Reported balance
Holding disclosure · report date 2022-10-14 · row 5
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 5 · Balance 12,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $5.31 · Expires 2026-04-26 | Direct | 17,000 |
Reported balance
Holding disclosure · report date 2022-10-14 · row 6
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 6 · Balance 17,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $7.08 · Expires 2026-06-08 | Direct | 25,000 |
Reported balance
Holding disclosure · report date 2022-10-14 · row 7
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 7 · Balance 25,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $6.23 · Expires 2026-09-01 | Direct | 35,000 |
Reported balance
Holding disclosure · report date 2022-10-14 · row 8
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 8 · Balance 35,000 |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.91 · Expires 2027-08-29 | Direct | 46,000 |
Reported balance
Holding disclosure · report date 2022-10-14 · row 9
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 9 · Balance 46,000 |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4A is being filed to correct the transaction code for the open market purchase made by Mr. Downey as originally notated as a grant or award in the Form 4 filed on October 18, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 14, 2022 Filed Oct 18, 2022 18:31 UTC Amendment | Lexaria Bioscience Corp. LEXX · Entity 7641 | Purchasecommon shares | 121 | $2.09 | $252.89 |
DisclosureSEC source: 0001855763-22-000020 · primary_doc.xml · nonDerivative · entry 2 Downey Gregory · CIK 0001855801 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,954 F1 · kind: This Form 4A is being filed to correct the transaction code for the open market purchase made by Mr. Downey as originally notated as a grant or award in the Form 4 filed on October 18, 2022. Read SEC document |
| October 14, 2022 Filed Oct 18, 2022 14:34 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | Grantcommon shares | 121 | $2.09 | $252.89 |
DisclosureSEC source: 0001855763-22-000018 · primary_doc.xml · nonDerivative · entry 2 Downey Gregory · CIK 0001855801 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,954 Read SEC document |
| August 29, 2022 Filed Aug 29, 2022 17:08 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 11,000 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001855763-22-000007 · primary_doc.xml · derivative · entry 8 Downey Gregory · CIK 0001855801 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,000 Underlying: Common Shares · 11,000 shares Expires 2027-08-29 Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 13:19 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 10,000 | $0.00 Strike: $6.23 | $0.00 |
DisclosureSEC source: 0001855763-21-000023 · primary_doc.xml · derivative · entry 7 Downey Gregory · CIK 0001855801 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Shares · 10,000 shares Expires 2026-09-01 Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 12:38 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 8,000 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001855763-21-000014 · primary_doc.xml · derivative · entry 6 Downey Gregory · CIK 0001855801 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 8,000 shares Expires 2026-06-08 Read SEC document |
| May 07, 2021 Filed Jun 9, 2021 12:32 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | OtherStock Options · Derivative | 8,000 | $0.00 Strike: $9.60 | $0.00 |
DisclosureSEC source: 0001855763-21-000013 · primary_doc.xml · derivative · entry 7 Downey Gregory · CIK 0001855801 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Shares · 8,000 shares Expires 2025-04-23 F1 · kind: Cancelled Options Read SEC document |
| April 26, 2021 Filed Apr 27, 2021 17:21 UTC | Lexaria Bioscience Corp. LEXX · Entity 7641 | GrantStock Options · Derivative | 5,000 | $0.00 Strike: $5.31 | $0.00 |
DisclosureSEC source: 0001855763-21-000007 · primary_doc.xml · derivative · entry 6 Downey Gregory · CIK 0001855801 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 5,000 shares Expires 2026-04-26 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.